SMO and pancreatic neoplasm: To test our hypothesis, pancreatic cancer cells incubated in hypoxia condition were treated with or without either cyclopamine (a SMO antagonist) or GLI1 siRNA to inhibit Hh signaling, and then compared the resulting phenotype with control-treated cells.